This open-label, single arm study will evaluate the safety and efficacy of RoActemra/Actemra
(tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an
inadequate response to disease-modifying antirheumatic drugs (DMARDs) or anti-TNF. Patients
will receive RoActemra/Actemra at a dose of 8 mg/kg (max 800 mg) intravenously every 4 weeks
for a total of 6 infusions. Non-biologic DMARD therapy may be continued throughout the study.
Anticipated time on study treatment is 24 weeks.